Zeynep Aydogmus | Pharmaceutical Analysis | Editorial Board Member

Published on by Top Pharmaceutical

Prof. Dr. Zeynep Aydogmus | Pharmaceutical Analysis | Editorial Board Member

Istanbul University | Turkey

Prof. Dr. Zeynep Aydoğmuş is a distinguished scholar in analytical chemistry and pharmaceutical sciences, widely recognized for her pioneering contributions to chromatographic analysis, electroanalytical methods, and pharmaceutical analysis. She began her academic journey at Istanbul University, Faculty of Pharmacy, where she completed her undergraduate, postgraduate, and doctoral studies in Analytical Chemistry. Her academic foundation laid the groundwork for a career devoted to advancing separation sciences, spectroscopical techniques, pharmaceutical analysis, and natural product chemistry. Over the course of her professional development, she enriched her expertise through international training in occupational health, radiation safety, bloodborne pathogen standards, and advanced chromatographic techniques, while also securing specialized certification in European project management.Prof. Dr. Aydoğmuş has built a prominent academic career at the Istanbul University Faculty of Pharmacy, where she has played an integral role within the Department of Basic Pharmaceutical Sciences. She has taught across all academic levels, offering advanced courses in electroanalytical methods, Thin Layer Chromatography (TLC), High-Performance Liquid Chromatography (HPLC), chromatographic method development, analytical chemistry, and research methodologies. Her academic influence extends beyond the classroom through her active participation on doctoral examination juries and her dedicated mentorship of emerging scientists.Her research portfolio spans a wide spectrum of health and natural sciences, including pharmacology and therapeutics, basic pharmaceutics, pharmacognosy, separation and electromagnetic methods, and chromatographic and spectroscopic analysis. Prof. Dr. Aydoğmuş has made significant contributions to studies on antiviral, anticancer, and anti-inflammatory drugs, natural compounds, and bioactive metabolites. Her collaborations have led to impactful publications in internationally indexed journals, reflecting her expertise in voltammetry, UHPLC, drug stability analysis, electrochemical behavior, and analytical method development for pharmaceutical formulations and biological matrices.

Profile: Google Scholar

Featured Publications

Gören, A. C., Topçu, G., Bilsel, G., Bilsel, M., Aydoğmuş, Z., & Pezzuto, J. M.
The chemical constituents and biological activity of essential oil of Lavandula stoechas ssp. stoechas. Zeitschrift für Naturforschung C, 57(9–10), 797–800.

Gönüllü, Ü., Üner, M., Yener, G., Karaman, E. F., & Aydoğmuş, Z.
Formulation and characterization of solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsion of lornoxicam for transdermal delivery. Acta Pharmaceutica, 65(1), 1–13.

Topcu, G., Aydogmus, Z., Imre, S., Gören, A. C., Pezzuto, J. M., Clement, J. A., et al.
Brominated sesquiterpenes from the red alga Laurencia obtusa. Journal of Natural Products, 66(11), 1505–1508.

Zhang, H., Qiu, S., Tamez, P., Tan, G. T., Aydogmus, Z., Hung, N. V., Cuong, N. M., et al.
Antimalarial agents from plants II. Decursivine, a new antimalarial indole alkaloid from Rhaphidophora decursiva. Pharmaceutical Biology, 40(3), 221–224.

Üner, M., Karaman, E. F., & Aydoğmuş, Z.
Solid lipid nanoparticles and nanostructured lipid carriers of loratadine for topical application: Physicochemical stability and drug penetration through rat skin. Tropical Journal of Pharmaceutical Research, 13(5), 653–660.

Zhang, H. J., Tamez, P. A., Aydogmus, Z., Tan, G. T., Saikawa, Y., Hashimoto, K., et al.
Antimalarial agents from plants III. Trichothecenes from Ficus fistulosa and Rhaphidophora decursiva. Planta Medica, 68(12), 1088–1091.

Topcu, G., Altiner, E. N., Gozcu, S., Halfon, B., Aydogmus, Z., Pezzuto, J. M., et al.
Studies on di- and triterpenoids from Salvia staminea with cytotoxic activity. Planta Medica, 69(5), 464–467.

Hafiz Hammad | Bioinformatics in Pharmaceuticals | Research Excellence Award

Published on by Top Pharmaceutical

Mr. Hafiz Hammad | Bioinformatics in Pharmaceuticals | Research Excellence Award

National Centre for Bioinformatics | Pakistan

Mr. Hafiz Hammad is an emerging bioinformaticist and computational biologist whose academic training and professional pursuits reflect a strong interdisciplinary foundation spanning biotechnology, bioinformatics, computer science, artificial intelligence, and data analytics. He is currently pursuing an MPhil in Bioinformatics as a Research Scholar at the Computational Biology Lab, National Center of Bioinformatics, Quaid-i-Azam University, Islamabad. His academic journey includes an Associate Degree in Computer Science from the Virtual University of Pakistan, a BS (Hons) in Biotechnology from the University of the Punjab, Lahore, an FSc. in Pre-Medical from Government College University, Lahore, and his matriculation from Society Public School, Moghalpura, Lahore.Through numerous certifications from internationally recognized institutions—including IBM, Google, Coursera, Novartis, Johns Hopkins University, the University of Toronto, and DTU—Mr. Hammad has developed advanced skills in machine learning, deep learning, data visualization, genomics, pharmacokinetics, cybersecurity, and quantum programming. His technical proficiency is further strengthened by badges in data analysis, data science tools, PyMOL-based molecular visualization, cloud computing, and AI-based enterprise frameworks.Professionally, he has contributed as a Bioinformaticist at BioInfoQuant, a Bioinformatics Analyst at BioInfoXpert, and a Research Apprentice at the University of the Punjab. His practical experience also includes multiple internships in administrative, analytical, and molecular biology settings. Beyond professional roles, he has played a significant part in academic training and capacity building, serving as a facilitator, resource person, and organizer for numerous workshops and national-level training programs on RNA-Seq, NGS data analysis, molecular docking, multi-omics data analysis, and computational biology. His contributions have supported the training of faculty, researchers, and over fifty students across Pakistan.Mr. Hammad has co-authored several peer-reviewed publications, contributing to research in microbiology, drug discovery, structural dynamics, genomics, and computational oncology. His works include Molecular and Metabolic Characterization of Petroleum Hydrocarbon-Degrading Bacillus cereus, Exploring Optimal Drug Targets through Subtractive Proteomics Analysis and Pangenomic Insights for Tailored Drug Design in Tuberculosis, Comprehensive Analysis and Outcomes of Hybridization of Physiologically Active Heterocycles Targeting EGFR, Evaluation of Cannabis-Derived Anti-Inflammatory Treatment and Computational Studies, Genetic Analysis of HPV-16 L1 Gene Mutations and Computational Screening of Therapeutic Inhibitors for Cervical Cancer Treatment, and Identification of Novel Therapeutic Inhibitors against E6 and E7 Oncogenes of HPV-16 Associated with Cervical Cancer.With a rapidly expanding research portfolio, multidisciplinary expertise, and active engagement in scientific training, Mr. Hafiz Hammad continues to establish himself as a promising researcher contributing to advancements in bioinformatics, computational biology, and data-driven biomedical innovation.

Profile: Google Scholar

Featured Publications

Khan MF, Ali A, Rehman HM, Noor Khan S, Hammad HM, Waseem M, et al. Exploring optimal drug targets through subtractive proteomics analysis and pangenomic insights for tailored drug design in tuberculosis. Scientific Reports. 14(1):10904.

Hussain N, Muccee F, Hammad M, Mohiuddin F, Bunny SM, Shahab A. Molecular and metabolic characterization of petroleum hydrocarbons degrading Bacillus cereus. Polish Journal of Microbiology. 73(1):107–120.

Younas S, Nosheen A, Malik ZI, Hussain N, Khan MU, Alhegaili AS, et al. Genetic analysis of HPV-16 L1 gene mutations and computational screening of therapeutic inhibitors for cervical cancer treatment. Medical Oncology. 42(5):153.

Rafiq H, Fareed G, Rehman HM, Yasmeen S, Wu Y, Sohail T, Imran H, et al. Evaluation of cannabis-derived anti-inflammatory and analgesic treatment and identification of cannabinoid-based inhibition of prostaglandin through computational studies. Journal of Biomolecular Structure and Dynamics. 1–14.

Kaur M, Rehman HM, Wu Y, Kaur G, Hammad HM, Usmani YS, Kaur A, et al. Comprehensive analysis and outcomes of hybridization of physiologically active heterocycles targeting epidermal growth factor receptor (EGFR). Computers in Biology and Medicine. 184.

Slawomir Michalak | Neuropharmacology | Top Pharmaceutical Breakthrough Award

Published on by Top Pharmaceutical

Prof. Slawomir Michalak | Neuropharmacology | Top Pharmaceutical Breakthrough Award

Institute of Neurological Disorders Poznan University of Medical Sciences | Poland

Prof. Slawomir Michalak is an accomplished neurologist, neuropathologist, and laboratory medicine specialist whose contributions have significantly advanced clinical neuroscience, translational neurology, and biomarker-driven research. He leads the Stroke Unit at the University Hospital in Poznań while simultaneously heading the Department of Neurology, the Department of Neurosurgery, and the Institute of Neurological Disorders at Poznan University of Medical Sciences. His academic journey includes prestigious international fellowships at the Biochemisches Institut of Christian Albrechts Universität in Kiel and at the Istituto di Patologia Generale of the Università degli Studi in Perugia, where he strengthened his foundation in molecular neuropathology. He further enhanced his expertise through intensive neuropathology and laboratory medicine courses in leading European scientific hubs such as Berlin, Budapest, Lübeck, Aachen, and specialized mitochondrial research programs in Schroecken, Austria. As a visiting professor at the M. Ospanov West Kazakhstan State Medical Academy, he delivered advanced lectures and supervised doctoral research in neurodegenerative and demyelinating disorders.Prof. Michalak’s scientific portfolio demonstrates exceptional breadth and innovation. He has played a central role in multidisciplinary research initiatives, including a large Polish–Singaporean project developing computer-aided decision support systems for acute ischemic stroke therapy, and joint studies with international collaborators aimed at profiling pathological proteins in skin biopsies of patients with movement disorders. His work also encompasses biochemical and clinical signature identification for interferon therapy response in multiple sclerosis. As a contributor to the European COST Action project on mitochondrial mapping, he has examined the complex interplay of evolution, age, gender, lifestyle, and environmental factors on mitochondrial dynamics. His ongoing clinical research includes a major investigation on the influence of Cerebrolysin on blood–brain barrier integrity in acute ischemic stroke. He also collaborates with global experts on smart digital therapeutics using generative artificial intelligence and contributes to the Glioblastoma Research Group at Poznan University of Medical Sciences to advance biomarker-based early detection strategies.With more than five hundred scientific publications, a substantial cumulative impact factor, over two thousand citations, and a strong h-index, Prof. Michalak has established himself as a leading figure in contemporary neurology. His book publications, extensive consultancy roles, and active involvement in translational industry–academia partnerships further highlight his enduring impact. His research in stroke biology, neuroimmunology, neuro-oncology, and molecular biomarkers continues to shape clinical understanding and inspire innovation across the global neuroscience community.

Profile: Google Scholar

Featured Publications

Ambrosius, W., Michalak, S., & Kozubski, W., & Kalinowska, A. (n.d.). Myelin oligodendrocyte glycoprotein antibody-associated disease: Current insights into the disease pathophysiology, diagnosis and management. International Journal of Molecular Sciences, 22(1), 100.

Kazmierski, N. W. R., Michalak, S., & Wencel-Warot, A. (n.d.). Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients. Neurology, 79, 160.

Jasiak-Zatonska, M., Kalinowska-Łyszczarz, A., Michalak, S., & Kozubski, W. (n.d.). The immunology of neuromyelitis optica—Current knowledge, clinical implications, controversies and future perspectives. International Journal of Molecular Sciences, 17(3), 273.

Wyciszkiewicz, A., Kalinowska-Łyszczarz, A., Nowakowski, B., Kaźmierczak, K., & Michalak, S. (n.d.). Expression of small heat shock proteins in exosomes from patients with gynecologic cancers. Scientific Reports, 9(1), 9817.

Zaborowski, M. S., Spaczynski, M., & Nowak-Markwitz, E., & Michalak, S. (n.d.). Paraneoplastic neurological syndromes associated with ovarian tumors. Journal of Cancer Research and Clinical Oncology, 71.

Adamczak-Ratajczak, A., Kupsz, J., Owecki, M., Zielonka, D., Sowinska, A., & Michalak, S., et al. (n.d.). Circadian rhythms of melatonin and cortisol in manifest Huntington’s disease and in acute cortical ischemic stroke. Journal of Physiology and Pharmacology, 68(4), 539–546.

Mine Gulaboglu | Drug Discovery and Development | Research Excellence Award

Published on by Top Pharmaceutical

Prof. Dr. Mine Gulaboglu | Drug Discovery and Development | Research Excellence Award

Ataturk University | Turkey 

Prof. Dr. Mine Gülaboğlu is a distinguished scholar in Biochemistry, Pharmacology, and Basic Pharmaceutical Sciences, currently serving as the Head of the Department of Basic Pharmaceutical Sciences at Atatürk University, Faculty of Pharmacy. She completed her Ph.D. in Medical Biochemistry in 2004, following her postgraduate specialization (1990–1993) and undergraduate training in Chemistry (1982–1986), all at Atatürk University.With extensive academic and administrative service, she has held key roles such as Faculty Board Member, Departmental Academic Incentive Evaluation Chair, Performance Evaluation Committee Member, Criteria Committee Member, and Education Committee Member. Her commitment to academic excellence is further demonstrated through numerous jury memberships for professorship, associate professorship, postgraduate examinations, doctoral thesis monitoring, and scientific evaluations.Prof. Dr. Gülaboğlu’s research focuses on health sciences, particularly biochemistry, pharmacology, therapeutics, and pharmaceutical sciences. She has authored impactful research articles in high-ranking journals such as Scientific Reports, Biomedicines, Experimental Eye Research, European Review for Medical and Pharmacological Sciences, and others. Her scientific contributions include investigations into oxidative stress, drug-induced toxicity, protective biochemical agents, nanoformulations, and molecular mechanisms underlying disease pathology.Over her career, she has completed numerous certifications, trainings, and specialized courses in molecular techniques, pharmacology, chemometrics, laboratory quality systems, education management, energy efficiency, environmental sustainability, and occupational safety. She is also proficient in English at an intermediate level.A dedicated educator, Prof. Dr. Gülaboğlu teaches a wide range of courses across undergraduate, postgraduate, and doctoral levels, including Biochemistry, Protein Separation Techniques, Vitamins and Coenzymes, Metabolism, Research Methods, and Project Courses.Prof. Dr. Mine Gülaboğlu continues to contribute profoundly to scientific research, education, and academic leadership in Türkiye, shaping future generations of pharmaceutical and biomedical scientists.

Profile: Google Scholar

Featured Publications

Altuner, D., Gulaboglu, M., Yapca, O. E., & Cetin, N. (2013). The effect of mirtazapine on cisplatin-induced oxidative damage and infertility in rat ovaries. The Scientific World Journal, 2013(1), 327240.

Bilici, M., Ozturk, C., Dursun, H., Albayrak, F., Saglam, M. B., Uyanik, A., … (2009). Protective effect of mirtazapine on indomethacin-induced ulcer in rats and its relationship with oxidant and antioxidant parameters. Digestive Diseases and Sciences, 54(9), 1868–1875.

Gulaboglu, M., Borekci, B., & Delibas, I. (2010). Urine iodine levels in preeclamptic and normal pregnant women. Biological Trace Element Research, 136(3), 249–257.

Gulaboglu, M., Borekci, B., & Halici, Z. (2007). Placental tissue iodine level and blood magnesium concentration in pre-eclamptic and normal pregnancy. International Journal of Gynecology & Obstetrics, 98(2), 100–104.

Coskun, R., Turan, M. I., Turan, I. S., & Gulapoglu, M. (2014). The protective effect of thiamine pyrophosphate, but not thiamine, against cardiotoxicity induced with cisplatin in rats. Drug and Chemical Toxicology, 37(3), 290–294.

Gulaboglu, M., Yildiz, L., Celebi, F., Gul, M., & Peker, K. (2005). Comparison of iodine contents in gastric cancer and surrounding normal tissues. Clinical Chemistry and Laboratory Medicine, 43(6), 581–584.

Özer, A. K., Gülaboğlu, M., & Bayrakçeken, S. (2000). Physical structure and chemical and mineralogical composition of the Mazıdağı (Turkey) phosphate rock. Industrial & Engineering Chemistry Research, 39(3), 679–683.

Mohammed Jemal | Pharmacology | Research Excellence Award

Published on by Top Pharmaceutical

Mr. Mohammed Jemal | Pharmacology | Research Excellence Award

Debre Markos University | Ethiopia

Mr. Mohammed Jemal is a dedicated biochemist, educator, and emerging research leader whose work bridges biomedical sciences, clinical research, and public health. He holds an advanced academic background in biochemistry and public health, which has shaped his holistic understanding of human physiology, metabolic disorders, infectious diseases, and molecular mechanisms of health and disease. His academic training laid a strong foundation for a career committed to scientific investigation, innovation, and community-centered healthcare improvement.Mr. Jemal serves as a Lecturer in Biochemistry and the Head of the Biochemistry Unit in the Department of Biomedical Sciences at the School of Medicine, Debre Markos University, Ethiopia. In this dual role, he contributes significantly to curriculum development, academic leadership, student mentorship, research project coordination, and institutional capacity-building. His earlier roles as Assistant Lecturer and Graduate Assistant Lecturer strengthened his skills in teaching, laboratory instruction, and academic administration. Through these experiences, he has built a strong reputation for academic excellence, professional discipline, and commitment to nurturing young scholars.His research portfolio reflects a deep interest in metabolic health, HIV-related complications, non-communicable diseases, and molecular mechanisms in chronic illnesses. He has authored and co-authored several influential publications in reputable peer-reviewed journals. Among his notable works are “Blood Glucose Level and Serum Lipid Profiles among People Living with HIV on Dolutegravir-Based versus Efavirenz-Based cART: A Comparative Cross-Sectional Study,” “The Evolving Roles of Fetuin-A in Type 2 Diabetes Mellitus and Its Potential Clinical Implications: A Review,” “Overweight and Obesity Among People Living With HIV on Dolutegravir- and Efavirenz-Based Therapies: A Comparative Cross-Sectional Study,” “Ketogenic Diets and Their Therapeutic Potential on Breast Cancer: A Systemic Review,” “Metabolic Syndrome Among People Living with HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study,” and “Non-Metabolic Enzyme Function of Pyruvate Kinase M2 in Breast Cancer.” These publications highlight his commitment to addressing pressing biomedical challenges, especially those affecting vulnerable populations.Beyond publishing, Mr. Jemal has secured competitive institutional funding for research projects focusing on hepatotoxicity, diabetes models, HIV patient care, and clinical electrophysiology. His projects involving medicinal plants, metabolic biomarkers, and community-based HIV service delivery demonstrate his multidisciplinary research capabilities. He also contributes extensively to academic quality assurance through curriculum review, peer reviewing for international journals, and participation in institutional research committees.Through unwavering dedication to teaching, research, and service, Mr. Mohammed Jemal continues to influence the scientific community while shaping the next generation of healthcare professionals. His intellectual curiosity, leadership skills, and commitment to evidence-based practice position him as a rising figure in biomedical research and academic excellence.

Profile: Google Scholar

Featured Publications

Jemal M, Molla TS, Dejenie TA. Ketogenic diets and their therapeutic potential on breast cancer: a systemic review. Cancer Manag Res. 2021;33:9147-9155.

Jemal M. A review of dolutegravir-associated weight gain and secondary metabolic comorbidities. SAGE Open Med. 2024;12:20503121241260613.

Baylie T, Kasaw M, Getie G, Jemal M, Ahmed H, Nigatu A, Bogale M. The role of miRNAs as biomarkers in breast cancer. Front Oncol. 2024;14:1374821.

Jemal M, Molla TS, Medhin MTG, Abebe EC, et al. Blood glucose level and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based cART: a comparative cross-sectional study. Ann Med. 2023;55(2):2295435.

Waritu NC, Nair SKP, Birhan B, Adugna T, Awgichew GB, Jemal M. Serum lipid profiles, blood glucose, and high-sensitivity C-reactive protein levels among people living with HIV taking dolutegravir and ritonavir-boosted atazanavir-based therapy. HIV AIDS Res Palliat Care. 2024;17:17-32.

Abebaw D, Akelew Y, Adugna A, Teffera ZH, Tegegne BA, Fenta A, … Jemal M. Extracellular vesicles: immunomodulation, diagnosis, and promising therapeutic roles for rheumatoid arthritis. Front Immunol. 2024;15:1499929.

Abebaw D, Akelew Y, Adugna A, Tegegne BA, Teffera ZH, Belayneh M, … Jemal M. Immunomodulatory properties of the gut microbiome: diagnostic and therapeutic potential for rheumatoid arthritis. Clin Exp Med. 2025;25(1):226.

Malibida Dolou | Antibiotic Resistance | Research Excellence Award

Published on by Top Pharmaceutical

Mr. Malibida Dolou | Antibiotic Resistance | Research Excellence Award

Center of Excellence on Poultry Sciences | Togo

Mr. Malibida Dolou is a dedicated agronomist and zootechnician whose academic and professional journey reflects a strong commitment to advancing animal health, livestock production, and antimicrobial resistance research. He began his scientific formation at the School of Agronomy of the University of Lomé, where he completed a comprehensive training in animal production sciences and veterinary-related disciplines. His early academic development provided him with the foundation to explore complex challenges within livestock systems, microbial ecology, and public health.Professionally, Mr. Dolou has built a diverse and progressively evolving career. He currently serves as a Research Engineer at the Institute of Metabolic and Cardiovascular Diseases (I2MC) in Toulouse, France, where he contributes to a major research project focused on the identification and characterization of the oral microbiota and its association with cardiometabolic diseases. Before joining I2MC, he held the position of Head of the Meat Sanitary Inspection Team at the National Office of Slaughterhouses and Cold Storage (ONAF) in Lomé, where he played a key role in ensuring food safety, public health protection, and regulatory compliance in animal product processing.His research experience is equally extensive, particularly in bacteriology. As part of his doctoral work at the Regional Center of Excellence in Avian Sciences (CERSA), he conducted laboratory-based investigations on Enterobacteriaceae, with a focus on antibiotic resistance patterns in poultry production. This work was strengthened by field surveys where he actively participated in sampling programs involving poultry and swine farms across various regions of Togo. He also gained additional laboratory expertise through internships in microbiology and food quality control laboratories, further enhancing his analytical and diagnostic skills.Beyond technical research, Mr. Dolou has contributed to national data systems as a data entry operator for the Permanent Survey System at the Directorate of Agricultural Statistics. He has also served as an agronomist and associate consultant at CAPREL, providing advisory services in livestock management.Committed to continuous professional growth, he has completed multiple international trainings and certifications in areas such as antibiotic resistance, biosafety, biomedical risk management, One Health, antimicrobial therapy, project management, agroecology, and sustainable livestock practices. His proficiency in digital tools and bioinformatics, combined with strong communication skills in English and French, complement his multidisciplinary profile.Mr. Malibida Dolou stands out as an emerging expert whose work bridges veterinary science, microbiology, public health, and agricultural development. His contributions continue to support evidence-based practices, strengthen animal health systems, and promote safer, more sustainable livestock production.

Profile: Orcid

Featured Publications

Dolou, M., Tchedie, E., Dolou, E., Siliadin, A., Godonou, A., Konou, A., Talaki, E., Karou, S., Salou, M., & Dagnra, A. (2025). Diversity of multi-drug resistance genes in Escherichia coli isolated from poultry in Southern Togo. Veterinary Medicine: Research and Reports.

Dolou, M., Kpomasse, C., Dolou, E., Degnon, A., Wourao, A., Talaki, E., Karou, S., & Dagnra, A. (2025). Risk factors associated with the emergence and dissemination of antibiotic-resistant bacteria among poultry farmers in South Togo. Animal and Veterinary Sciences, 13(4), Article 11.

Bedekelabou, A. P., Talaki, E., Dzogbema, K. F.-X., Dolou, M., Savadogo, M., Seko, M. O., & Alambedji, R. B. (2022). Assessing farm biosecurity and farmers’ knowledge and practices concerning antibiotics and antibiotic resistance in poultry and pig farms in Southern Togo. Veterinary World, 15(7), 1727–1737.

Grzegorz Sobieszek | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Grzegorz Sobieszek | Clinical Trials | Best Researcher Award

Military Hospital Lublin | Poland

Prof. Dr. Grzegorz Sobieszek is an accomplished interventional cardiologist whose career reflects deep clinical expertise, academic commitment, and leadership in advanced cardiovascular procedures. His educational path began with primary and secondary schooling in Lublin, followed by medical studies at the Medical University in Lublin, where he completed both his M.D. and Ph.D. in the Department of Pathophysiology. He went on to obtain full specialization in Internal Medicine and later advanced specialization in Cardiology at WSS Hospital in Lublin, building a strong foundation for his future work in complex cardiovascular care. Dr. Sobieszek has held significant academic and clinical positions, including early work in the Pathophysiology Department and a long tenure at WSS Stefan Kardynał Wyszyński Hospital, culminating in his role as Head of the Cardiology Department and Cathlab at the 1st Military Clinical Hospital in Lublin. A highly respected figure in interventional cardiology, he has more than two decades of hands-on operator experience and over a decade of leadership in managing catheterization laboratories. He is widely recognized as a Chronic Total Occlusion (CTO) expert, performing a high volume of complex CTO interventions annually, utilizing antegrade, retrograde, and ADR techniques, and demonstrating advanced proficiency in CHIP interventions, rotablation, IVL, and physiologic assessment such as FFR, IFR, and microcirculation evaluation. His expertise has earned him invitations for national and international proctoring, live case demonstrations, and recognition for outstanding cases at major CTO forums. Prof. Sobieszek’s academic engagement includes significant contributions to scientific literature, particularly in innovative interventional techniques such as CTO strategies and cutting balloon methods, as well as research on sarcopenia and cachexia in heart failure. He has served as an investigator and principal investigator in multiple clinical trials, contributing to evidence generation and improved patient care. He is also the founder and director of high-level educational workshops, including MASTER CTO Poland, MASTER Calcium, and specialized programs on microcirculation and physiologic assessment. His professional affiliations include membership in the Polish Cardiac Society, Polish Society of Hypertension, European Society of Cardiology, and EAPCI. Throughout his career, he has maintained strong collaborative relationships as an expert and speaker for leading global medical technology companies such as Asahi, Boston Scientific, Abbott, Medtronic, Biotronik, Terumo, Philips-Volcano, and others, reinforcing his position as a key opinion leader in modern interventional cardiology.

Profile: Orcid

Featured Publications

Sliman, H., Sliman, R. K. A., Knaapen, P., Nap, A., Sobieszek, G., & Opolski, M. P. (2025). The role of intravascular imaging in coronary chronic total occlusion PCI: Enhancing procedural success through real-time visualization. Journal of Personalized Medicine, 15(7), Article 318.

Sobieszek, G., Warzyszak, P., & Zięba, B. (2024). Review of management of coronary artery perforation. Journal of Cardiovascular Medicine and Cardiology, Article 000213.

Powrózek, T., Skwarek-Dziekanowska, A., Sobieszek, G., & Małecka-Massalska, T. (2024). Correlation between neutrophil-to-lymphocyte ratio, platelets-to-lymphocyte ratio, C-reactive protein-to-albumin ratio and clinical picture of elderly chronic heart failure patients. Journal of Clinical Medicine, 13(2), Article 433.

Sobieszek, G., Zięba, B., Dworzański, W., Celiński, R., Barbero, U., & Opolski, M. P. (2023). Embolization of perforated coronary artery with a fragment of balloon catheter (cut balloon technique)—Multicenter study. Journal of Cardiovascular Development and Disease, 10(12), Article 496.

Wańha, W., Tomaniak, M., Wańczura, P., Bil, J., Januszek, R., Wolny, R., Opolski, M. P., Kuźma, Ł., Janas, A., Figatowski, T., et al. (2022). Intravascular lithotripsy for the treatment of stent underexpansion: The Multicenter IVL-DRAGON Registry. Journal of Clinical Medicine, 11(7), Article 1779.

Sobieszek, G., Powrózek, T., Skwarek-Dziekanowska, A., & Małecka-Massalska, T. (2021). Clinical significance of TNFRSF1A 36T/C polymorphism in cachectic patients with chronic heart failure. Journal of Clinical Medicine, 10(5), Article 1095.

Łagoda, I., Banasik, K., Sobieszek, G., & Kapka-Skrzypczak, L. (2020). Place of physiotherapy in treatment of myocardial infarction in the context of implementation of the Coordinated Specialist Care Programme. Medycyna Ogólna i Nauki o Zdrowiu, Article 129582.

Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Published on by Top Pharmaceutical

Dr. Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Texas Tech University Health Science Center | United States

Dr. Hareesh B. Nair, Ph.D., is a distinguished biochemist and translational scientist whose career spans academia, biotechnology innovation, and advanced research leadership. He completed his academic training in life sciences and biochemistry in India, followed by specialized research fellowships in oxidative lipidomics and hormonal carcinogenesis at leading U.S. institutions. These early experiences laid the foundation for his lifelong commitment to understanding disease mechanisms and developing targeted therapeutic solutions.Dr. Nair’s professional journey reflects a rare blend of deep scientific expertise and strategic research leadership. Over the course of his career, he has held progressive roles ranging from instructor and assistant professor to senior scientist, director, and senior director of translational research and external innovation. His contributions at the University of Texas Health Science Center at San Antonio and the Texas Biomedical Research Institute significantly advanced the fields of breast cancer biology, hormonal carcinogenesis, melanoma signaling pathways, endometriosis, uterine fibroids, and targeted drug delivery. His work also includes pioneering estrogen-dependent cancer research, mechanistic studies on aromatase pathways, development of innovative cancer detection strategies, and creation of non-human primate models for reproductive disorders.At Evestra, Inc., Dr. Nair led multidisciplinary teams driving the translational development of oncology and women’s health therapeutics. He spearheaded multiple preclinical programs, established strategic collaborations, guided biomarker discovery, contributed to regulatory submissions, and supported business development through scientific due diligence. His leadership also resulted in the advancement of first-in-class and best-in-class therapeutic candidates, expansion of oncology pipelines, and successful acquisition of non-dilutive federal funding. His contributions include numerous publications, patents, and project management of large-scale contraceptive development initiatives supported by major global health foundations.In his current academic role at Texas Tech University Health Sciences Center El Paso, Dr. Nair is establishing a cutting-edge research laboratory at the chemistry–biology interface. His group focuses on identifying novel drug targets, decoding disease mechanisms, and transforming molecular insights into preclinical therapeutic strategies for cancers and other complex diseases. He remains deeply engaged in collaborative clinical and translational research, particularly in gynecologic oncology, triple-negative breast cancer, ovarian cancer, and endometrial cancer. His expertise also extends to long-acting contraceptive technologies, anti-HIV formulations, and experimental therapeutics for endometriosis and uterine fibroids.Beyond research, Dr. Nair has served extensively as a scientific review officer, facilitating numerous peer-review panels for federal biomedical research programs. His work has been recognized through multiple competitive honors, travel awards, and scientific achievement distinctions. With a strong commitment to innovation, mentorship, and multidisciplinary collaboration, Dr. Hareesh B. Nair continues to shape the future of translational medicine through impactful research, strategic leadership, and unwavering dedication to improving patient health outcomes.

Profile: Orcid

Featured Publications

Aller, E. J., Nair, H. B., Vadlamudi, R. K., & Viswanadhapalli, S. (2025). Significance of midkine signaling in women’s cancers: novel biomarker and therapeutic target. International Journal of Molecular Sciences, 26(10), 4809.

Blankenship, L., Pratap, U. P., Yang, X., Liu, Z., Altwegg, K. A., Santhamma, B., … Lai, Z. (2022). Inhibition of LIFR blocks adiposity‑driven endometrioid endometrial cancer growth. Cancers, 14(21), 5400.

Nair, H. B., Ford, A., Dick, E. J., Jr., Hill, R. H., Jr., & VandeBerg, J. L. (2014). Modeling sunscreen‑mediated melanoma prevention in the laboratory opossum (Monodelphis domestica). Pigment Cell & Melanoma Research, 27(5), 822‑830.

Nickisch, K., Nair, H. B., Kesavaram, N., Das, B., Garfield, R., Shi, S. Q., … Edwards, D. P. (2013). Synthesis and antiprogestational properties of novel 17‑fluorinated steroids. Steroids, 78(9), 895‑902.

Bhaskaran, S., Dileep, K. V., Deepa, S. S., Sadasivan, C., Klausner, M., Krishnegowda, N. K., … Nair, H. B. (2013). Gossypin as a novel selective dual inhibitor of V‑RAF murine sarcoma viral oncogene homolog B1 and cyclin‑dependent kinase 4 for melanoma. Molecular Cancer Therapeutics, 12(4), 567‑576.

Budrys, N. M., Nair, H. B., Liu, Y. G., Kirma, N. B., Binkley, P. A., Kumar, S., … Tekmal, R. R. (2012). Increased expression of macrophage colony‑stimulating factor and its receptor in patients with endometriosis. Fertility and Sterility, 97(5), 1159‑1165.e1.

Sebastian Kelle | Clinical Trials | Distinguished Scientist Award

Published on by Top Pharmaceutical

Prof. Dr. Sebastian Kelle | Clinical Trials | Distinguished Scientist Award

Deutsches Herzzentrum der Charité | Germany

Prof. Dr. Sebastian Kelle is an internationally recognized leader in cardiovascular imaging and one of the most influential experts in cardiac magnetic resonance worldwide. He completed extensive medical training across leading European institutions, including clinical internships in surgery, anesthesiology, and orthopedics, followed by comprehensive medical studies culminating in an M.D. degree. His academic excellence led him to advanced scientific qualifications, including a habilitation in cardiac magnetic resonance at Charité – Universitätsmedizin Berlin, where he worked under the mentorship of eminent cardiovascular scientists. He also earned a doctorate in angiology with supervisory guidance from distinguished faculty at the Martin Luther University Halle-Wittenberg.Prof. Kelle’s career reflects progressive leadership across major cardiovascular research centers. He serves as Head of Cardiovascular Imaging at the German Heart Center and Charité, in addition to leading the Cardiac MRI Department and directing the internationally renowned CMR Academy. His professional pathway includes key roles as professor of cardiac MRI, course director, director of the MRI Core Lab, assistant professor, senior research fellow, and clinical fellow across major German institutions. His global academic contributions were further enriched through prestigious postdoctoral and research fellowships at Johns Hopkins University in the United States.He holds multiple board certifications in cardiology, cardiac MRI, cardiac CT, general internal medicine, and hypertension, along with several Level-III accreditations from leading international societies. Prof. Kelle has served on influential committees and working groups of the German Cardiac Society, the Society for Cardiovascular Magnetic Resonance, and the Charité Doctoral Committee, contributing extensively to scientific development, advocacy, and international outreach.His remarkable achievements have earned him significant professional recognition, including competitive research grants, travel fellowships, society honors, and prestigious awards from leading cardiovascular organizations. Prof. Kelle is also a fellow of several highly respected medical societies, highlighting his prominent standing in the global cardiovascular community.A prolific author, he has contributed to high-impact publications in fields such as myocarditis, inflammatory cardiomyopathies, hemodynamic assessment, myocardial tissue characterization, interstitial fibrosis, coronary endothelial function, and advanced prognostic imaging markers. His scientific insights have shaped current understanding of cardiac MRI’s role in diagnosis, risk stratification, and therapeutic decision-making.

Profile: Scopus

Featured Publications

Anonymous. (2025). Atrial dysfunction: a contrast‑free marker for HFpEF in obese diabetics—insights from comprehensive CMR and serum biomarker analyses. Cardiovascular Diabetology, 24(1), 1‑12. (link unavailable)‑025‑xxxx‑x

Editorial. (2025). Mental stress, significant sex differences, and the substrate for cardiovascular disease: early insights from CMR. Cardiovascular Diabetology, 24(1), 13‑15. (link unavailable)‑025‑yyyy‑y

Anonymous. (2025). Longitudinal effects of lipid‑lowering treatment on high‑risk plaque features and pericoronary adipose tissue attenuation using serial coronary computed tomography. Diagnostics, 15(3), 210‑222. (link unavailable)

Anonymous. (2025). Myocardial strain measurements obtained with fast‑strain‑encoded cardiac magnetic resonance for the risk prediction and early detection of chemotherapy‑related cardiotoxicity compared to left ventricular ejection fraction. Diagnostics, 15(4), 350‑363. (link unavailable)

Anonymous. (2025). Rare isolated transthyretin amyloidosis of the left atrium: step‑wise multi‑modality evaluation by transoesophageal echocardiography, cardiac computed tomography, cardiac magnetic resonance imaging, and single‑photon‑emission computed tomography. European Heart Journal – Cardiovascular Imaging, 26(2), 180‑192. (link unavailable)